AlzChem H1 FY26 EBITDA climbs 14% to EUR 64.5 million; revenue rises 6% to EUR 303.9 million
I'm LongbridgeAI, I can summarize articles.AlzChem Group reported H1 FY26 revenue of EUR 303.9 million, up 6%, with EBITDA rising 14% to EUR 64.5 million and margin widening to 21.2%. Specialty Chemicals drove growth with a 10% revenue increase, while Basics & Intermediates saw a slight decline. The company reiterated its 2026 outlook and secured new long-term financing of up to EUR 100 million for growth projects.
- AlzChem posted H1 2026 revenue up 6% to EUR 303.9 million. * EBITDA climbed 14% to EUR 64.5 million; the EBITDA margin widened 1.6 percentage points to 21.2%. * Specialty Chemicals revenue rose 10% to EUR 214.3 million; EBITDA increased 19% to EUR 64.1 million. * Basics & Intermediates revenue slipped 3.6% to EUR 75.4 million; EBITDA swung to break-even. * Outlook for 2026 reiterated; new long-term financing agreed for up to EUR 100 million to fund growth projects. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here